Your browser doesn't support javascript.
loading
PAX5A and PAX5B isoforms are both efficient to drive B cell differentiation.
Cresson, Charlotte; Péron, Sophie; Jamrog, Laura; Rouquié, Nelly; Prade, Nais; Dubois, Marine; Hébrard, Sylvie; Lagarde, Stéphanie; Gerby, Bastien; Mancini, Stéphane J C; Cogné, Michel; Delabesse, Eric; Delpy, Laurent; Broccardo, Cyril.
Afiliação
  • Cresson C; Inserm, UMR1037 CRCT, F-31000, Université Toulouse III-Paul Sabatier, UMR1037 CRCT, Oncopole, F-31000 Toulouse, France.
  • Péron S; Université de Limoges-CNRS UMR 7276, F-87025 Limoges, France.
  • Jamrog L; Inserm, UMR1037 CRCT, F-31000, Université Toulouse III-Paul Sabatier, UMR1037 CRCT, Oncopole, F-31000 Toulouse, France.
  • Rouquié N; Inserm, UMR1037 CRCT, F-31000, Université Toulouse III-Paul Sabatier, UMR1037 CRCT, Oncopole, F-31000 Toulouse, France.
  • Prade N; Inserm, UMR1037 CRCT, F-31000, Université Toulouse III-Paul Sabatier, UMR1037 CRCT, Toulouse Hospital University, Oncopole, CS 53717, F-31000 Toulouse, France.
  • Dubois M; Inserm, UMR1037 CRCT, F-31000, Université Toulouse III-Paul Sabatier, UMR1037 CRCT, Oncopole, F-31000 Toulouse, France.
  • Hébrard S; Inserm, UMR1037 CRCT, F-31000, Université Toulouse III-Paul Sabatier, UMR1037 CRCT, Oncopole, F-31000 Toulouse, France.
  • Lagarde S; Inserm, UMR1037 CRCT, F-31000, Université Toulouse III-Paul Sabatier, UMR1037 CRCT, Toulouse Hospital University, Oncopole, CS 53717, F-31000 Toulouse, France.
  • Gerby B; Inserm, UMR1037 CRCT, F-31000, Université Toulouse III-Paul Sabatier, UMR1037 CRCT, Oncopole, F-31000 Toulouse, France.
  • Mancini SJC; Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, F-13009 Marseille, France.
  • Cogné M; Université de Limoges-CNRS UMR 7276, Institut Universitaire de France, F-87025 Limoges, France.
  • Delabesse E; Inserm, UMR1037 CRCT, F-31000, Université Toulouse III-Paul Sabatier, UMR1037 CRCT, Toulouse Hospital University, Oncopole, CS 53717, F-31000 Toulouse, France.
  • Delpy L; Université de Limoges-CNRS UMR 7276, F-87025 Limoges, France.
  • Broccardo C; Inserm, UMR1037 CRCT, F-31000, Université Toulouse III-Paul Sabatier, UMR1037 CRCT, Oncopole, F-31000 Toulouse, France.
Oncotarget ; 9(67): 32841-32854, 2018 Aug 28.
Article em En | MEDLINE | ID: mdl-30214688
ABSTRACT
Pax5 is the guardian of the B cell identity since it primes or enhances the expression of B cell specific genes and concomitantly represses the expression of B cell inappropriate genes. The tight regulation of Pax5 is therefore required for an efficient B cell differentiation. A defect in its dosage can translate into immunodeficiency or malignant disorders such as leukemia or lymphoma. Pax5 is expressed from two different promoters encoding two isoforms that only differ in the sequence of their first alternative exon. Very little is known regarding the role of the two isoforms during B cell differentiation and the regulation of their expression. Our work aims to characterize the mechanisms of regulation of the expression balance of these two isoforms and their implication in the B cell differentiation process using murine ex vivo analyses. We show that these two isoforms are differentially regulated but have equivalent function during early B cell differentiation and may have functional differences after B cell activation. The tight control of their expression may thus reflect a way to finely tune Pax5 dosage during B cell differentiation process.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article